$-0.98
(Market cap
$612 Mln
Revenue (TTM)
$98 Mln
P/E Ratio
71.5
P/B Ratio
11.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
52.5
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
77,750,400
10 Years Aggregate
CFO
$-101.60 Mln
EBITDA
$-147.53 Mln
Net Profit
$-150.68 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Chromadex Corp (CDXC)
| 27.4 | -13.8 | 19.6 | 71.6 | 46.7 | 13.3 | 6.2 |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Chromadex Corp (CDXC)
| 267.0 | -14.9 | -55.1 | -22.1 | 11.4 | 25.7 | -41.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Chromadex Corp (CDXC)
|
6.8 | 611.9 | 61.6 | 8.6 | 0.6 | 22.9 | 71.5 | 11.4 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Chromadex Corp (CDXC)
ChromaDex Corporation operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished... dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California. Read more
-
Co-Founder & Chairman
Mr. Frank Louis Jaksch Jr.
-
Co-Founder & Chairman
Mr. Frank Louis Jaksch Jr.
-
Headquarters
Los Angeles, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Chromadex Corp (CDXC)
What is the current share price of Chromadex Corp (CDXC) Today?
The share price of Chromadex Corp (CDXC) is $6.76 (NASDAQ) as of 17-Apr-2025 09:30 EDT. Chromadex Corp (CDXC) has given a return of 46.73% in the last 3 years.
What is the current PB & PE ratio of Chromadex Corp (CDXC)?
The P/E ratio of Chromadex Corp (CDXC) is 71.55 times as on 17-Apr-2025.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
What is the 52 Week High and Low of Chromadex Corp (CDXC)?
The 52-week high and low of Chromadex Corp (CDXC) are Rs -- and Rs -- as of 31-Aug-2026.
What is the market cap of Chromadex Corp (CDXC)?
Chromadex Corp (CDXC) has a market capitalisation of $ 612 Mln as on 17-Apr-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Chromadex Corp (CDXC)?
Before investing in Chromadex Corp (CDXC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.